| |
Focused on accelerating gene and cell therapy from clinical to commercial, OcyonBio built two processing facilities in Puerto Rico. See how the company is now benefiting from the island's highly skilled talent, tax benefits & much more.
|
|
Today’s Big NewsMar 7, 2024 |
| By Annalee Armstrong Novo Nordisk has blown its own drug Wegovy out of the water. The Danish pharma reported early results for a next-gen oral weight loss drug called amycretin, showing 13.1% weight loss after 12 weeks. |
|
|
|
By Fraiser Kansteiner By Eisai’s 2026 fiscal year—which ends in March 2027—the company figures its Alzheimer's disease drug Leqembi can bring home 290 billion Japanese yen (nearly $2 billion) in global revenues. Come fiscal year 2032, those sales could potentially swell to a whopping 1.3 trillion yen ($8.8 billion). In the near term, the company is dealing with some launch hurdles. |
By Conor Hale Smiths Medical has been urging healthcare providers to update tens of thousands of its hospital syringe pumps after identifying issues with outdated software, and now the FDA is helping to get the word out. |
By Kevin Dunleavy With President Joe Biden girding for a significant challenge from former President Donald Trump in his re-election bid in November, Biden undoubtedly will emphasize his success in leading the passage of the Inflation Reduction Act (IRA). Tonight, as Biden makes his State of the Union address, he is expected to reveal a push to double down on his drug price initiatives outlined in the IRA. |
|
Wednesday, March 13, 2024 | 11am ET / 8am PT Extractables and leachables are a hot topic in the pharmaceutical industry today. As single-use systems, devices, and routes of administration evolve, it is important to have a strategy that helps ensure you choose proper equipment and materials, file on time, avoid repeat studies, and more. Save your spot to be a part of this insightful discussion!
|
|
By Max Bayer Biogen's grander Alzheimer's strategy includes tau and future oral treatments. |
By Conor Hale Researchers may have found a way to make the invisible visible when it comes to detecting small yet life-threatening complications after surgery. |
By Angus Liu GSK has more trial evidence to support a potential comeback for its withdrawn antibody-drug conjugate Blenrep. And analysts are already assigning blockbuster sales figures to the medicine. |
By Max Bayer Arch- and Leaps-backed Boundless Bio is going public, likely the seventh biotech company to grace Wall Street in 2024. The company launched less than five years ago. |
By James Waldron Zymeworks has halted phase 2 plans for a HER2 antibody-drug conjugate while the biotech assesses the “evolving clinical landscape.” |
By Zoey Becker Starting on June 1, patients will only have to shell out a maximum of $35 per month for Boehringer Ingelheim inhalers in the U.S. |
Fierce podcastsDon’t miss an episode |
| | This week on “Podnosis,” Fierce Healthcare’s Anastassia Gliadkovskaysa sits down with NeuroFlow Chief Medical Officer Tom Zaubler, M.D., to discuss the barriers to the widespread adoption of measurement-based care in behavioral health. |
|
|---|
|
|
| Whitepaper This paper assesses the current state of the broad CNS market, reviewing key expectations for 2024. It addresses Alzheimer’s disease, biomarkers, and advances in psychiatry in detail. It also provides a high-level look at the pain market and the evolving regulatory environment. Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
